Related Experiment Video

Updated: Apr 18, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K

Tumor cell lysates as immunogenic sources for cancer vaccine design

Fermín E González1, Alejandra Gleisner, Felipe Falcón-Beas

  • 1a Millennium Institute on Immunology and Immunotherapy; Institute of Biomedical Sciences; Faculty of Medicine ; University of Chile ; Santiago , Chile.

Human Vaccines & Immunotherapeutics
|January 28, 2015
PubMed

Insights

Cancer vaccines using dendritic cells (DCs) show promise but face challenges. Using allogeneic tumor cell lysates offers a reproducible antigen source for more effective DC-based cancer immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Autologous dendritic cells (DCs) loaded with tumor-associated antigens (TAAs) are investigated for cancer therapy, stimulating antitumor responses and memory.
  • Patient refractoriness to current DC approaches necessitates improved antigen delivery strategies.
  • Various antigen sources, including peptides and tumor lysates, have been explored for DC loading.

Purpose of the Study:

  • To review the role of cancer cell-derived lysates as a source of antigens for therapeutic ex vivo dendritic cells.
  • To evaluate the potential of allogeneic tumor cell lysates for enhancing DC-based cancer immunotherapy.
  • To discuss the optimization of tumor cell lysate preparation for improved therapeutic efficacy.

Main Methods:

  • Review of existing literature on dendritic cell-based cancer vaccines.
  • Analysis of different antigen sources for DC loading, including autologous and allogeneic tumor lysates.
  • Evaluation of the immunological response induced by DCs loaded with tumor cell lysates.

Main Results:

  • Allogeneic tumor cell lysates provide a reproducible pool of diverse antigens, overcoming limitations of autologous sources.
  • DCs loaded with allogeneic tumor cell lysates can induce potent immunological responses against cancer cells.
  • Optimizing tumor cell lysate preparation is critical for maximizing the efficacy of DC-based therapies.

Conclusions:

  • Cancer cell-derived lysates are a valuable antigen source for ex vivo therapeutic DCs.
  • Allogeneic tumor cell lysate-loaded DCs represent a promising strategy for advanced cancer patients, potentially improving survival.
  • Further optimization of lysate preparation is key to advancing DC-based cancer immunotherapy.
Keywords:
AM, Cytokine-activated monocytesAgs, AntigensCDAMs, Cell death-associated moleculesCRT, CalreticulinCTLs, Cytotoxic T lymphocytesDAMPsDAMPs, Damage-associated molecular patternsDCs, Dendritic cellsDTH, Delayed-type IV hypersensitivityGM-CSF, Granulocyte and macrophage colony stimulating factorHMGB1, High-mobility group box 1 proteinHSPs, Heat shock proteinsICD, Immunogenic cell deathMAAs, Melanoma-associated antigensMHC, Major histocompatibility complexMM, Malignant melanomaNKT, Natural killer T cellPAMPs, Pathogen-associated molecular patternsPBMCs, Peripheral blood mononuclear cellsPCCL, Prostate cancer cell lysatePD1, Programmed cell death protein 1PRRs, Pattern recognition receptorsPSA, Prostate specific antigenRAGE, Receptor for advanced glycation endproductsSNPs, Single nucleotide polymorphismsTAAs, Tumor-associated antigensTAPCells, Tumor antigen presenting cellsTCRs, T cell receptorsTLRs, Toll-like receptorsTNF, Tumor necrosis factorTRIMEL, Allogeneic melanoma cell lysateTRIPRO, Allogeneic prostate cell lysateToll-like receptorsTregs, Regulatory T lymphocytescancer immunotherapydendritic cellsimmunogenic cell death

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K
In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

3.2K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.4K